Integra LifeSciences reaffirms full-year earnings guidance and projects third-quarter revenue between $410M and $425M. Integra LifeSciences maintained its adjusted earnings per share forecast for Q2 2026 at $2.40 to $2.50. The company also guided third-quarter revenue to a
Corcept Therapeutics reports Q2 2026 revenue of $256.1 million, up 32% year-over-year, driven by strong sales of Korlym and Lifyorli. Corcept Therapeutics posted Q2 2026 revenue of $256.1 million, a 32% increase from the same period last year. The growth was fueled by $208
Anika Therapeutics raises its 2026 adjusted EBITDA margin outlook and revenue growth projections after Q2 performance. Anika Therapeutics revised its 2026 adjusted EBITDA margin forecast to 13%-17%, up from prior guidance, while raising its revenue growth outlook to 5%-10%
Utility forecasts regional demand growth of 2.6 gigawatts through 2030, underpinning a $37.5 billion capital expenditure plan. WEC Energy Group raised its five-year capital plan to $37.5 billion as it projects 2.6 gigawatts of regional demand growth by 2030. The company ci
Generac projects $450M in data center revenue by Q2 2026 and boosts its commercial and industrial growth outlook. Generac Holdings revised its full-year Commercial & Industrial (C&I) segment growth outlook to the low 30s%, citing strong Q2 2026 performance. The company rep
The aluminum producer forecasts adjusted EBITDA of $980M-$1.02B and over $300M free cash flow by 2026 amid aerospace and recycling growth. Constellium (CSTM) announced a 2026 target of $980M-$1.02B in adjusted EBITDA and more than $300M in free cash flow. The outlook follo
The pharmaceutical firm raises full-year revenue targets for AUSTEDO, AJOVY, and UZEDY after Q2 2026 performance beats expectations. Teva Pharmaceutical Industries raised its 2026 revenue midpoint by $75 million, citing stronger-than-expected sales of its key drugs. The co
Microsoft reports Q4 revenue of $90.0 billion and guides FY27 capex to $175 billion, driving shares higher. Microsoft shares jumped 7% after hours following stronger-than-expected Q4 results and a bullish capex outlook. Adjusted EPS of $4.74 beat estimates of $4.24, while
Nabors targets $20M-$30M free cash flow in 2026 Nabors Industries expects full-year EBITDA to range from $920M to $930M. The company's Q2 2026 adjusted EBITDA was $222 million, exceeding expectations. Several significant milestones were achieved, including
Prosperity Bancshares aims for a 3.70%-3.75% net interest margin exit in 2026 following its Stellar Bancorp merger completion. Prosperity Bancshares has targeted a net interest margin (NIM) exit range of 3.70% to 3.75% for 2026 after completing its merger with Stellar Banc
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.